AAPL 183.36 5.9701% MSFT 406.8 2.2522% GOOG 169.01 0.3265% GOOGL 167.21 0.3541% AMZN 186.235 0.8202% NVDA 887.83 3.4562% META 452.05 2.3479% TSLA 181.14 0.6277% TSM 141.56 3.9125% LLY 734.97 -2.7702% V 268.47 0.3214% AVGO 1278.11 3.1924% JPM 190.51 -0.6% UNH 492.45 -0.1055% NVO 123.05 -0.7821% WMT 59.82 0.1842% LVMUY 168.5 2.1584% XOM 116.02 -0.1893% LVMHF 841.0 1.8789% MA 443.58 0.5622%

Aspen Pharmacare Holdings Limited

Healthcare US APNHF

9.205USD
-(-%)

Last update at 2024-05-03T13:30:00Z

Day Range

9.219.21
LowHigh

52 Week Range

4.819.21
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 6555.00M 8134.00M 5989.00M 5602.00M 2771.00M
Minority interest - - 0.00000M 2.00M 2.00M
Net income 5228.00M 6488.00M 4806.00M 4664.00M 6463.00M
Selling general administrative 1677.00M 1481.00M 1843.00M 1598.00M 5129.00M
Selling and marketing expenses 2922.00M 2915.00M 3082.00M 3432.00M -
Gross profit 18408.00M 18306.00M 17789.00M 19333.00M 19656.00M
Reconciled depreciation 1788.00M 1713.00M 1653.00M 1603.00M 1274.00M
Ebit 8784.00M 8992.00M 8196.00M 9077.00M 9316.00M
Ebitda 10572.00M 10705.00M 9849.00M 10680.00M 6377.00M
Depreciation and amortization 1788.00M 1713.00M 1653.00M 1603.00M -
Non operating income net other - - - - 0.00000M
Operating income 7822.00M 8671.00M 7072.00M 7060.00M 9366.00M
Other operating expenses 31766.00M 29768.00M 28574.00M 29683.00M 104.00M
Interest expense 1324.00M 765.00M 1205.00M 1578.00M 2332.00M
Tax provision 1327.00M 1646.00M 1191.00M 991.00M 774.00M
Interest income 509.00M 92.00M 108.00M 141.00M 213.00M
Net interest income -815.00000M -737.00000M -1097.00000M -1482.00000M -2189.00000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 1327.00M 1646.00M 1191.00M 991.00M 671.00M
Total revenue 40709.00M 38606.00M 37766.00M 38647.00M 38872.00M
Total operating expenses 9465.00M 9468.00M 8597.00M 10369.00M 29506.00M
Cost of revenue 22301.00M 20300.00M 19977.00M 19314.00M 19216.00M
Total other income expense net -1267.00000M -537.00000M -1083.00000M -1458.00000M -6431.00000M
Discontinued operations - - 8.00M 1284.00M 4784.00M
Net income from continuing ops 5228.00M 6488.00M 4798.00M 4611.00M 1997.00M
Net income applicable to common shares 5228.00M 6488.00M 4806.00M 4664.00M 6463.00M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 134284.00M 111375.00M 109684.00M 133169.00M 122316.00M
Intangible assets 63104.00M 53651.00M 54882.00M 73040.00M 66468.00M
Earning assets - - - - -
Other current assets 14.00M -2000.00000M 69.00M 11.00M 50.00M
Total liab 48048.00M 40433.00M 44057.00M 63952.00M 68103.00M
Total stockholder equity 86236.00M 70942.00M 65627.00M 69215.00M 54211.00M
Deferred long term liab 822.00M 987.00M 1352.00M 1502.00M 1178.00M
Other current liab 104.00M 346.00M 351.00M 421.00M 325.00M
Common stock 2017.00M 2017.00M 2089.00M 2089.00M 2089.00M
Capital stock 2017.00M 2017.00M 2089.00M 2089.00M 2089.00M
Retained earnings 58134.00M 54341.00M 50756.00M 45911.00M 41246.00M
Other liab 3525.00M 6456.00M 7040.00M 9854.00M 8351.00M
Good will 5596.00M 5007.00M 4621.00M 5375.00M 4649.00M
Other assets 3009.00M 2919.00M 3602.00M 4685.00M 4160.00M
Cash 10912.00M 6183.00M 8546.00M 7093.00M 8977.00M
Cash and equivalents - - - - -
Total current liabilities 23148.00M 23395.00M 36751.00M 18079.00M 20039.00M
Current deferred revenue 11168.00M 7743.00M 8495.00M 7987.00M 7538.00M
Net debt 18370.00M 16064.00M 16328.00M 35228.00M 38984.00M
Short term debt 7907.00M 11665.00M 24608.00M 6302.00M 8248.00M
Short long term debt 7907.00M 10329.00M 24443.00M 6112.00M 8234.00M
Short long term debt total 29282.00M 22247.00M 24874.00M 42321.00M 47961.00M
Other stockholder equity 26085.00M 14584.00M 12782.00M 21215.00M 10876.00M
Property plant equipment 18897.00M 16224.00M 15226.00M 14833.00M 12065.00M
Total current assets 44500.00M 34561.00M 32705.00M 36738.00M 36152.00M
Long term investments - - - - 0.00000M
Net tangible assets 18358.00M 13271.00M 7476.00M -7698.00000M -15728.00000M
Short term investments - - - - 0.00000M
Net receivables 10087.00M 14615.00M 10437.00M 12886.00M 12095.00M
Long term debt 21375.00M 105.00M - 35583.00M 39707.00M
Inventory 19606.00M 15763.00M 13409.00M 16413.00M 14648.00M
Accounts payable 3969.00M 3641.00M 3297.00M 3369.00M 3928.00M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 343.00M 329.00M 305.00M 324.00M 801.00M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 89784.00M 76814.00M 76979.00M 96431.00M 86164.00M
Capital lease obligations - 345.00M 431.00M 626.00M 20.00M
Long term debt total - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -3421.00000M -2161.00000M 9763.00M 1624.00M 3238.00M
Change to liabilities -984.00000M 871.00M 580.00M -699.00000M -1219.00000M
Total cashflows from investing activities -3421.00000M -2161.00000M 9763.00M 1624.00M 3238.00M
Net borrowings 1171.00M -1623.00000M -15598.00000M -11424.00000M -9758.00000M
Total cash from financing activities -420.00000M -4676.00000M -15648.00000M -11465.00000M -11265.00000M
Change to operating activities - -2652.00000M -2652.00000M -2652.00000M -2652.00000M
Net income 7822.00M 8671.00M 6638.00M 7420.00M 6463.00M
Change in cash 2522.00M -984.00000M 338.00M -531.00000M -1966.00000M
Begin period cash flow 4971.00M 5955.00M 5617.00M 6148.00M 8114.00M
End period cash flow 7493.00M 4971.00M 5955.00M 5617.00M 6148.00M
Total cash from operating activities 5520.00M 5374.00M 6825.00M 8260.00M 6002.00M
Issuance of capital stock - - - - -
Depreciation 1788.00M 1713.00M 1653.00M 1603.00M 935.00M
Other cashflows from investing activities 60.00M 569.00M 13413.00M 4370.00M 13357.00M
Dividends paid 1455.00M 1196.00M 1196.00M 1196.00M 1437.00M
Change to inventory -2701.00000M -2168.00000M -280.00000M -727.00000M -1028.00000M
Change to account receivables 327.00M -1355.00000M 348.00M 1618.00M 869.00M
Sale purchase of stock -136.00000M -1857.00000M -50.00000M -41.00000M -29.00000M
Other cashflows from financing activities 7756.00M 14038.00M 14479.00M 14051.00M -41.00000M
Change to netincome 1862.00M -175.00000M -266.00000M 1832.00M -306.00000M
Capital expenditures 3181.00M 2697.00M 3431.00M 2690.00M 2442.00M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -3358.00000M -2652.00000M 648.00M 192.00M -1378.00000M
Stock based compensation 135.00M 58.00M 67.00M 49.00M 37.00M
Other non cash items -432.00000M -780.00000M -434.00000M -122.00000M -133.00000M
Free cash flow 2339.00M 2677.00M 3394.00M 5570.00M 2419.00M

Fundamentals

  • Previous Close 9.21
  • Market Cap4690.19M
  • Volume0
  • P/E Ratio14.38
  • Dividend Yield1.98%
  • EBITDA10189.00M
  • Revenue TTM40709.00M
  • Revenue Per Share TTM91.65
  • Gross Profit TTM 18902.00M
  • Diluted EPS TTM0.64

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APNHF
Aspen Pharmacare Holdings Limited
- -% 9.21 14.38 - 0.11 0.88 0.14 0.58
ZTS
Zoetis Inc
-0.16 0.10% 167.07 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
0.40 1.22% 32.73 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
0.23 0.14% 162.23 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
0.10 0.75% 13.37 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Limited

Aspen Place, Durban, South Africa

Key Executives

Name Title Year Born
Mr. Stephen Bradley Saad Group CEO & Exec. Director 1964
Mr. Sean M. Capazorio Group CFO & Exec. Director 1967
Ms. Lorraine Hill Group Chief Operations Officer & Responsible Pharmacist 1964
Mr. Michael Guy Attridge B.Com., BCom, CA(SA) Group Chief Advisor 1961
Mr. Reginald Haman Grad. Dip., MBA, ND, NHD, PGDBA Group Chief Corp. Services Officer 1975
Ms. Zizipho Mmango Group Chief Strategic Devel. Officer 1985
Mr. Riaan Verster ACIS, BProc, L.L.B., L.L.M., LLB, LLM Company Sec., Group Governance Officer & Group Compliance Officer 1976
Mr. Trevor Julian Ziman Regional Chief Exec. Officer of Asia Pacific 1972
Mr. Stavros Nicolaou Group Sr. Exec. of Strategic Trade 1965
Mr. Carnie van der Linde Group Commercial Head 1969

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).